Interactions of theophylline with drug, diet, some xenobiotics, and habits and their toxicological outcomes

KARAKILIÇ, M. Evvah; CHAREHSAZ, Muhammed; gurbay, Aylin; Şahin, Gönül

Interactions of theophylline with drug, diet, some xenobiotics, and habits and their toxicological outcomes

Muhammed CHAREHSAZ, (Hacettepe Üniversitesi, Eczacılık Fakültesi, Farmasötik Teknoloji Anabilim Dalı, Ankara, Türkiye)

Aylin GÜRBAY, (Hacettepe Üniversitesi, Eczacılık Fakültesi, Farmasötik Teknoloji Anabilim Dalı, Ankara, Türkiye)

M. Evvah KARAKILIÇ, (Hacettepe Üniversitesi, Tıp Fakültesi, Acil Tıp Anabilim Dalı, Ankara, Türkiye)

Gönül ŞAHİN (Hacettepe Üniversitesi, Eczacılık Fakültesi, Farmasötik Teknoloji Anabilim Dalı, Ankara, Türkiye)

Journal of Clinical and Analytical Medicine

3 1

Yıl: 2012 Cilt: 3 Sayı: 1 Sayfa Aralığı: 117 - 122 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Interactions of theophylline with drug, diet, some xenobiotics, and habits and their toxicological outcomes

Öz:

İlaç tedavisinde sıklıkla karşılaşılan in vitro ve in vivo etkileşmeler ile toksi-kolojik sonuçları güvenli tedavi için önemlidir. Bazı ilaçların etkisini arttırmak için yararlı etkileşme olarak tanımlananlar bilerek uygulanır. Ancak bu etkileşmelerin örnekleri sınırlı sayıdadır. Diğer taraftan toksikolojik açıdan önemli sonuçlara neden olan istenmeyen ve zararlı etkileşmeler yaygındır. Terapötik penceresi dar olan ilaçlarla tedavi sırasında bu tip etkileşmeler daha kolay gelişir. Astım ve kronik obstruktif akciğer hastalığı (KOAH) tedavisinde kullanılan teofilinin de terapötik penceresi dardır. Bu nedenle sunulan bu derlemede teofilinin ilaç, diyet, ksenobiyotik, bitkisel ürün ve alışkanlıklarla etkileşmelerinden kaynaklanan bazı önemli örnekler ve toksikolojik sonuçları verilmiştir.

Anahtar Kelime: Gıda-ilaç etkileşimleri Ksenobiyotik Herb-ilaç etkileşimleri Teofilin İlaç etkileşimleri

Konular: Genel ve Dahili Tıp

Teofilinin ilaç, diyet, bazı ksenobiyotik ve alışkanlıklarla etkileşmesi ve toksikolojik sonuçları

Öz:

In vitro and in vivo interactions which are commonly met during drug therapy and their toxicological outcomes are important. In order to increase effect of certain drugs, interactions, which are called as beneficial interactions, are intentionally applied. However, examples of these interactions are in limited number. On the other hand, untoward and hazardous interactions that cause very important outcomes in toxicological point of view are common. These types of interactions develop more easily during therapy with drugs have a narrow therapeutic window. Theophylline which is used in the treatment of asthma and chronic obstructive pulmonary disease (COPD) has also a narrow therapeutic window. Therefore, in the present review, some important examples resulted from interactions of theophylline with drug, diet, xenobi-otic, herbal product, habits and their toxicological outcomes have been given.

Anahtar Kelime: Theophylline Drug Interactions Food-Drug Interactions Xenobiotics Herb-Drug Interactions

Konular: Genel ve Dahili Tıp

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Bellibaş SE, editor. Rasyonel İlaç Rehberi. İzmir: Egem Tıbbi Yayıncılık; 1994.
2. Kayaalp SO, editor. Rasyonel Tedavi Yönünden Tıbbi Farmakoloji. Ankara: Hacettepe Taş Kitapçılık; 2005.
3. Lu FC, Kacew S, editors. Lu's Basic Toxicology, Fundamentals, Target Organs and Risk Assessment. London: Taylor & Francis; 2002.
4. Şahin G, Girgin G. İlaç-Besin, İlaç-Alkol ve İlaç-Bitkisel Kökenli Ürün Etkileşmeleri. Mised 2003; 5-6: 92-109.
5. Clark WG, Brater DC, Johnson AR, editors. Goth's Medical Pharmacology. Washington D.C: Mosby; 2002.
6. Abernethy DR, Arnold GJ, Azarnoff D, editors. Mosby's Drug Consult. St. Louis: Mosby Inc, 2002.
7. Jonkman JH, Nicholson KG, Farrow PR, Eckert M, Grasmeijer G, Oosterhuis B, et al. Effects of alpha-interferon on theophylline pharmacokinetics and metabolism. Br J Clin Pharmacol 1989; 27(6): 795-802.
8. Atkinson AJ, Abernethy DR, Daniels CE, Dedrick RL, Markey SP, editors. Principles of Clinical Pharmacology. London: Elsevier; 2007.
9. Kobayashi K, Nakajima M, Chiba K, Yamamoto T, Tani M, Ishizaki T, et al. Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. Br J Clin Pharmacol 1998; 45(4): 361-368.
10. Fuhr U, Anders EM, Mahr G, Sorgel F, Staib AH. Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. An-timicrob Agents Chemother 1992; 36(5): 942-948.
11. Bertram G. Katzung editor. Basic & Clinical Pharmacology. McGraw-Hill; 2003.
12. Segev S, Rehavi M, Rubinstein E. Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor. Antimicrob Agents Chemother 1 988; 32(11): 1624-1626.
13. Spivey JM, Laughlin PH, Goss TF, Nix DE. Theophylline toxicity secondary to ciprofloxacin administration. Ann Emerg Med 1991; 20(10): 1131 -1134.
14. Yao C, Kunze KL, Kharasch ED, Wang Y, Trager WF, Ragueneau I, et al. Fluvox-amine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. Clin Pharmacol Ther 2001; 70(5): 415-424.
15. Colli A, Buccino G, Cocciolo M, Parravicini R, Elli GM, Scaltrini G. Ticlopidine-theophylline interaction. Clin Pharmacol Ther 1987; 41(3): 358-362.
16. Koch KM, Ricci BM, Hedayetullah NS, Jewell D, Kersey KE. Effect of alosetron on theophylline pharmacokinetics. Br J Clin Pharmacol 2001; 52(5): 596-600.
17. Ahn HC, Lee YC. The clearance of theophylline is increased during the initial period of tuberculosis treatment. Int J Tub ere Lung Dis 2003; 7(6): 587-591.
18. Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 2005; 97(3): 125-134.
19. Bapiro TE, Sayi J, Hasler JA, Jande M, Rimoy G, Masselle A, et al. Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans. Eur J Clin Pharmacol 2005; 61 (10): 755-761.
20. Rasmussen BB, Jeppesen U, Gaist D, Brosen K. Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. Ther Drug Monit 1997; 19(1): 56-62.
21. Meyer UA. Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Yale J Biol Med 1996; 69(3): 203-209.
22. Iliopoulou A, Aldhous ME, Johnston A, Turner P. Pharmacokinetic interaction between theophylline and erythromycin. Br J Clin Pharmacol 1982; 14(4): 495-499.
23. Nahata M. Drug interactions with azithromycin and the macrolides: an overview. J Antimicrob Chemother 1996; 37 Suppl C: 133-142.
24. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997; 44(2): 190-194.
25. Dekhuijzen PN, Koopmans PP. Pharmacokinetic profile of zafirlukast. Clin Phar-macokinet 2002; 41 (2): 105-114.
26. Zhou S, Chan E, Lim LY, Boelsterli UA, Li SC, Wang J, et al. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 2004; 5(5): 41 5-442.
27. Busby M, Lesko LJ. Pharmacokinetic interaction between theophylline and chloramphenicol in rats. Drug Metab Dispos 1987; 15(2): 204-206.
28. Park JY, Kim KA, Kim SL. Chloramphenicol is a potent inhibitor of cytochrome P450 isoforms CYP2C19 and CYP3A4 in human liver microsomes. Antimicrob Agents Chemother 2003; 47(11): 3464-3469.
29. Darwish M, Kirby M, Robertson P, Hellriegel ET. Interaction profile of ar-modafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet 2008; 47(1): 61 -74.
30. Lejus C, Fautrel A, Malledant Y, Guillouzo A. Inhibition of cytochrome P450 2E1 by propofol in- hupnan and porcine liver microsomes. Biochem Pharmacol 2002; 64(7): 1151-1156.
31. Frye RF, Branch RA. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects. Br J Clin Pharmacol 2002; 53(2): 155-162.
32. Undem BJ, Lichtenstein LM. Drug Used in the Treatment of Asthma. In: Hard-man JG, Limbird LE, Goodman Oilman A, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill; 2001. p. 733-754.
33. Roach SS, editor. Introductory Clinical Pharmacology. Lippincott Williams & Wilkins; 2006.
34. Richards D, Aronson J, editors. Oxford Handbook of Practical Drug Therapy New York: Oxford University Press; 2005.
35. Nowack R. Review article: cytochrome P450 enzyme, and transport protein mediated herb-drug interactions in renal transplant patients: grapefruit juice, St John's Wort - and beyond! Nephrology (Carlton) 2008; 13(4): 337-347.
36. Ishihara K, Kushida H, Yuzurihara M, Wakui Y, Yanagisawa T, Kamei H, et al Interaction of drugs and Chinese herbs: pharmacokinetic changes of tolbutamide and diazepam caused by extract of Angelica dahurica. J Pharm Pharmacol 2000; 52(8): 1023-1029.
37. Frank A, Unger M. Analysis of frankincense from various Boswellia species with inhibitory activity on human drug metabolising cytochrome P450 enzymes using liquid chromatography mass spectrometry after automated on-line extraction. J Chromatogr A 2006; 1112(1 -2): 255-262.
38. Foti RS, Wahlstrom JL. The role of dietary supplements in cytochrome P450-mediated drug interactions. Pharmacokinetics and Drug Metabolism 2008; 7(2): 66-84.
39. Tirillini B. Grapefruit: the last decade acquisitions. Fitoterapia 2000; 71 Suppl 1:29-37.
40. Ken lehi Fujita MH, Norito Takamura, Keishi Yamasaki, Tomomi Iwakiri, Mana-bu Okumura, Hirofumi Kodama, Masatoshi Yamaguchi, Tsuyomu Ikenoue, Kazuhiko Arimori. Inhibitory Effects of Citrus Fruits on Cytochrome P450 3A (CYP3A) Activity in Humans. Biol. Pharm. Bull 2003; 26(9): 1371-1373.
41. Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 2004; 75(1): 89-100.
42. Ueng YF, Tsai TH, Don MJ, Chen RM, Chen TL. Alteration of the pharmacokinetics of theophylline by rutaecarpine, an alkaloid of the medicinal herb Evodia rutaecarpa, in rats. J Pharm Pharmacol 2005; 57(2): 227-232.
43. Tang J, Sun J, Zhang Y, Li L, Cui F, He Z. Herb-drug interactions: Effect of Ginkgo biloba extract on the pharmacokinetics of theophylline in rats. Food Chem Toxicol 2007; 45(12): 2441-2445.
44. Tian M, Yan H, Row KH. Extraction of glycyrrhizic acid and glabridin from licorice. Int J Mol Sci 2008; 9(4): 571-577.
45. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000; 7(4): 273-282.
46. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002; 54(4): 349-356.
47. Hammerness P, Basch E, Ulbricht C, Barrette EP, Foppa I, Basch S, et al. St John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics 2003; 44(4): 271-282.
48. Saruwatari A, Okamura S, Nakajima Y, Narukawa Y, Takeda T, Tamura H. Pomegranate juice inhibits sulfoconjugation in Caco-2 human colon carcinoma cells. J Med Food 2008; 11 (4): 623-628.
49. Foster BC, Vandenhoek S, Hana J, Krantis A, Akhtar MH, Bryan M, et al. In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine 2003; 10(4): 334-342.
50. Braganza G, Chaudhuri R, Thomson NC. Treating patients with respiratory disease who smoke. Ther Adv Respir Dis 2008; 2(2): 95-107.

APA	CHAREHSAZ M, gurbay A, KARAKILIÇ M, Şahin G (2012). Interactions of theophylline with drug, diet, some xenobiotics, and habits and their toxicological outcomes. , 117 - 122.
Chicago	CHAREHSAZ Muhammed,gurbay Aylin,KARAKILIÇ M. Evvah,Şahin Gönül Interactions of theophylline with drug, diet, some xenobiotics, and habits and their toxicological outcomes. (2012): 117 - 122.
MLA	CHAREHSAZ Muhammed,gurbay Aylin,KARAKILIÇ M. Evvah,Şahin Gönül Interactions of theophylline with drug, diet, some xenobiotics, and habits and their toxicological outcomes. , 2012, ss.117 - 122.
AMA	CHAREHSAZ M,gurbay A,KARAKILIÇ M,Şahin G Interactions of theophylline with drug, diet, some xenobiotics, and habits and their toxicological outcomes. . 2012; 117 - 122.
Vancouver	CHAREHSAZ M,gurbay A,KARAKILIÇ M,Şahin G Interactions of theophylline with drug, diet, some xenobiotics, and habits and their toxicological outcomes. . 2012; 117 - 122.
IEEE	CHAREHSAZ M,gurbay A,KARAKILIÇ M,Şahin G "Interactions of theophylline with drug, diet, some xenobiotics, and habits and their toxicological outcomes." , ss.117 - 122, 2012.
ISNAD	CHAREHSAZ, Muhammed vd. "Interactions of theophylline with drug, diet, some xenobiotics, and habits and their toxicological outcomes". (2012), 117-122.

APA	CHAREHSAZ M, gurbay A, KARAKILIÇ M, Şahin G (2012). Interactions of theophylline with drug, diet, some xenobiotics, and habits and their toxicological outcomes. Journal of Clinical and Analytical Medicine, 3(1), 117 - 122.
Chicago	CHAREHSAZ Muhammed,gurbay Aylin,KARAKILIÇ M. Evvah,Şahin Gönül Interactions of theophylline with drug, diet, some xenobiotics, and habits and their toxicological outcomes. Journal of Clinical and Analytical Medicine 3, no.1 (2012): 117 - 122.
MLA	CHAREHSAZ Muhammed,gurbay Aylin,KARAKILIÇ M. Evvah,Şahin Gönül Interactions of theophylline with drug, diet, some xenobiotics, and habits and their toxicological outcomes. Journal of Clinical and Analytical Medicine, vol.3, no.1, 2012, ss.117 - 122.
AMA	CHAREHSAZ M,gurbay A,KARAKILIÇ M,Şahin G Interactions of theophylline with drug, diet, some xenobiotics, and habits and their toxicological outcomes. Journal of Clinical and Analytical Medicine. 2012; 3(1): 117 - 122.
Vancouver	CHAREHSAZ M,gurbay A,KARAKILIÇ M,Şahin G Interactions of theophylline with drug, diet, some xenobiotics, and habits and their toxicological outcomes. Journal of Clinical and Analytical Medicine. 2012; 3(1): 117 - 122.
IEEE	CHAREHSAZ M,gurbay A,KARAKILIÇ M,Şahin G "Interactions of theophylline with drug, diet, some xenobiotics, and habits and their toxicological outcomes." Journal of Clinical and Analytical Medicine, 3, ss.117 - 122, 2012.
ISNAD	CHAREHSAZ, Muhammed vd. "Interactions of theophylline with drug, diet, some xenobiotics, and habits and their toxicological outcomes". Journal of Clinical and Analytical Medicine 3/1 (2012), 117-122.